Medicines for Malaria Ventures (MMVs) mission is to discover, develop and deliver new, effective and affordable antimalarial drugs to reduce the death and illness from malaria, and support its eventual elimination. MMV supports directly SDG 3 and contributes to the SDG1, SDG 7, SDG 9 and SDG17. With its focus on pregnant women and women in reproductive age, MMV also contributes to the SDG 5 on gender equality and the target on access to sexual and reproductive health.

MMV uses public, private and philanthropic funds to catalyse innovative R&D, focusing on malaria, where private sector investment has been sorely lacking. MMV occupies a unique place in the antimalarial drug development space and is recognized as the leading Product-Development Partnership in the field of research and development of antimalarial drugs, with an additional, strong access facilitation focus. MMV has built a strong network of more than 400 partners in over 50 countries, including universities and research institutes, pharmaceutical and biotech companies, clinical investigators, clinical research organizations and government agencies. This extensive network of partners has enabled MMV to assemble the largest and most diverse pipeline of candidate malaria drugs in history. Improving access to new, effective medicines is one of MMVs major achievements. With its expert cohort of partners, MMV has successfully established networks for drug screening and development, and for open access to data and antimalarial compounds.

MMV has built up an extensive network of clinical trial sites and laboratories in malaria-affected countries, and has invested in strengthening the capacities of these sites, including IT and laboratory infrastructure and staff training. To date, MMV has built up a network of 107 clinical centres, increasing the research capacity of 30 malaria-endemic countries. Through MMVs investment in staff training, there are now multiple clinical trial sites, notably in Africa, generating high-quality real-world efficacy and safety data needed to inform local policy and treatment recommendations. MMV also supports the publication of articles on an open access basis, with study designs made accessible on clinicaltrials.gov., MMVs open-source compound libraries (the Malaria Box and the Pathogen Box) provide researchers with 800 drug compounds available free of charge to further R&D in neglected tropical diseases.

MMV is governed by a Board of Directors, whose responsibility is to ensure that the management is efficiently executing the objectives of MMV through oversight of the annual budget and work plan. The Board meets at least twice a year and is made up of a maximum of 18 members who are chosen for their scientific, medical and public health expertise in malaria and related fields, their research and management competence as well as their experience in business, finance and fundraising. The Board, which is supported by an Executive Committee and an Audit and Finance Committee, also appoints the Chief Executive Officer, who leads MMV and is supported in this function by an Executive Leadership Team. Three committees complete the governance structure of MMV: an Expert Scientific Advisory Committee (ESAC), which helps identify the best projects worthy of inclusion in the MMV portfolio and monitors progress through an annual review of all projects; an Access and Product Management Advisory Committee (APMAC), which advises the MMV Access Team on appropriate strategies to achieve its goals; and a Global Safety Board (GSB), which is mandated to conduct a thorough scientific and ethical review at each major project milestone beyond clinical phase I of the R&D process, through to registration and distribution.

42 governments; 41 NGOs and IOs; 139 research and academic institutions; 108 clinical centres; 57 pharmaceutical companies; 24 biotechnology companies.